Tumor-associated autoantibodies in combination with alpha-fetoprotein for detection of early stage hepatocellular carcinoma.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
08
2019
accepted:
10
04
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
25
7
2020
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) continues to be a leading challenge in modern oncology. Early detection via blood-based screening tests has the potential to cause a stage-shift at diagnosis and improve clinical outcomes. Tumor associated autoantibodies (TA-AAbs) have previously shown the ability to distinguish HCC from patients with high-risk liver disease. This research aimed to further show the utility of TA-AAbs as biomarkers of HCC and assess their use in combination with Alpha-fetoprotein (AFP) for detection of HCC across multiple tumor stages. Levels of circulating G class antibodies to 44 recombinant tumor associated antigens and circulating AFP were measured in the serum of patients with HCC, non-cancerous chronic liver disease (NCCLD) and healthy controls via enzyme-linked immunosorbent assay (ELISA). TA-AAb cut-offs were set at the highest Youden's J statistic at a specificity ≥95.00%. Panels of TA-AAbs were formed using net reclassification improvement. AFP was assessed at a cut-off of 200 ng/ml. Sensitivities ranged from 1.01% to 12.24% at specificities of 95.96% to 100.00% for single TA-AAbs. An ELISA test measuring a panel of 10 of these TA-AAbs achieved a combined sensitivity of 36.73% at a specificity of 89.89% when distinguishing HCC from NCCLD controls. At a cut-off of 200 ng/ml, AFP achieved a sensitivity of 31.63% at a specificity of 100.00% in the same cohort. Combination of the TA-AAb panel with AFP significantly increased the sensitivity for stage one (40.00%) and two (55.00%) HCC over the TA-AAb panel or AFP alone. A panel of TA-AAbs in combination with AFP could be clinically relevant as a replacement for measuring levels of AFP alone in surveillance and diagnosis strategies. The increased early stage sensitivity could lead to a stage shift with positive prognostic outcomes.
Sections du résumé
BACKGROUND
Hepatocellular carcinoma (HCC) continues to be a leading challenge in modern oncology. Early detection via blood-based screening tests has the potential to cause a stage-shift at diagnosis and improve clinical outcomes. Tumor associated autoantibodies (TA-AAbs) have previously shown the ability to distinguish HCC from patients with high-risk liver disease. This research aimed to further show the utility of TA-AAbs as biomarkers of HCC and assess their use in combination with Alpha-fetoprotein (AFP) for detection of HCC across multiple tumor stages.
METHODS
Levels of circulating G class antibodies to 44 recombinant tumor associated antigens and circulating AFP were measured in the serum of patients with HCC, non-cancerous chronic liver disease (NCCLD) and healthy controls via enzyme-linked immunosorbent assay (ELISA). TA-AAb cut-offs were set at the highest Youden's J statistic at a specificity ≥95.00%. Panels of TA-AAbs were formed using net reclassification improvement. AFP was assessed at a cut-off of 200 ng/ml.
RESULTS
Sensitivities ranged from 1.01% to 12.24% at specificities of 95.96% to 100.00% for single TA-AAbs. An ELISA test measuring a panel of 10 of these TA-AAbs achieved a combined sensitivity of 36.73% at a specificity of 89.89% when distinguishing HCC from NCCLD controls. At a cut-off of 200 ng/ml, AFP achieved a sensitivity of 31.63% at a specificity of 100.00% in the same cohort. Combination of the TA-AAb panel with AFP significantly increased the sensitivity for stage one (40.00%) and two (55.00%) HCC over the TA-AAb panel or AFP alone.
CONCLUSIONS
A panel of TA-AAbs in combination with AFP could be clinically relevant as a replacement for measuring levels of AFP alone in surveillance and diagnosis strategies. The increased early stage sensitivity could lead to a stage shift with positive prognostic outcomes.
Identifiants
pubmed: 32374744
doi: 10.1371/journal.pone.0232247
pii: PONE-D-19-22047
pmc: PMC7202612
doi:
Substances chimiques
Antigens, Neoplasm
0
Autoantibodies
0
alpha-Fetoproteins
0
Banques de données
figshare
['10.6084/m9.figshare.9249809']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0232247Subventions
Organisme : Medical Research Council
ID : MR/K01532X/1
Pays : United Kingdom
Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: Authors CW, IM, JM, CPK, JA, GH and AM are employees of Oncimmune ltd. Authors CW, IM, JA and AM are named inventors on patent WO2018096351 related to these results. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Hepatoma Res. 2018;4:
pubmed: 29376136
Cancer Epidemiol. 2012 Feb;36(1):82-8
pubmed: 22018955
Annu Rev Immunol. 2003;21:807-39
pubmed: 12615893
Cancer Lett. 2001 Mar 26;164(2):189-95
pubmed: 11179834
PLoS One. 2015 Jun 03;10(6):e0128235
pubmed: 26039628
Liver Cancer. 2018 Sep;7(3):235-260
pubmed: 30319983
Ann Surg Oncol. 2012 Jul;19 Suppl 3:S375-84
pubmed: 21681378
Med Sci Monit. 2018 Sep 06;24:6218-6228
pubmed: 30188879
Mol Cells. 2017 Jan;40(1):54-65
pubmed: 28152297
Int J Oncol. 2012 Sep;41(3):1061-7
pubmed: 22692946
Int J Clin Exp Pathol. 2015 Apr 01;8(4):3513-28
pubmed: 26097535
J Gastroenterol Hepatol. 2006 Aug;21(8):1281-5
pubmed: 16872310
J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22
pubmed: 15042359
Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):735-43
pubmed: 19822090
PLoS One. 2012;7(7):e40759
pubmed: 22815807
Med Oncol. 2013 Jun;30(2):503
pubmed: 23430442
Tumour Biol. 2012 Oct;33(5):1319-26
pubmed: 22492236
Clin Mol Hepatol. 2017 Sep;23(3):239-248
pubmed: 28706177
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
Semin Cancer Biol. 2018 Dec;53:75-89
pubmed: 30171980
Cancer Sci. 2008 May;99(5):952-7
pubmed: 18341653
Gastroenterology. 2009 Mar;136(3):1012-24
pubmed: 19150350
J Thorac Dis. 2013 Oct;5(5):618-25
pubmed: 24255775
Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12
pubmed: 17569110
J Thorac Oncol. 2016 Mar;11(3):334-45
pubmed: 26896032
J Proteome Res. 2008 Feb;7(2):611-20
pubmed: 18161940
Clin Cancer Res. 2011 Mar 15;17(6):1474-80
pubmed: 21138858
J Transl Med. 2015 Feb 12;13:55
pubmed: 25880432
World J Gastroenterol. 2013 Mar 21;19(11):1811-9
pubmed: 23555170
Am J Gastroenterol. 2006 Mar;101(3):524-32
pubmed: 16542289
Mol Oncol. 2014 Jul;8(5):1043-53
pubmed: 24785097
Cancer Cell. 2017 Jul 10;32(1):57-70.e3
pubmed: 28648284
Breast Cancer Res Treat. 2012 Feb;131(3):891-8
pubmed: 21509525
Cancer Lett. 2009 Aug 28;281(2):144-50
pubmed: 19304375
J Proteome Res. 2005 Jul-Aug;4(4):1123-33
pubmed: 16083262
Ann Oncol. 2010 Aug;21(8):1687-93
pubmed: 20124350
Gastroenterology. 2018 May;154(6):1706-1718.e1
pubmed: 29425931
Psychometrika. 1947 Jun;12(2):153-7
pubmed: 20254758
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2161-81
pubmed: 24057574
Clin Cancer Res. 2004 Jul 1;10(13):4332-41
pubmed: 15240519
Trends Cancer. 2017 Mar;3(3):198-213
pubmed: 28718432
Risk Manag Healthc Policy. 2012;5:49-54
pubmed: 22826645
PLoS One. 2014 Aug 05;9(8):e103867
pubmed: 25093332
World J Gastroenterol. 2016 Mar 7;22(9):2837-43
pubmed: 26973422
Cancer Lett. 2010 Mar 1;289(1):32-9
pubmed: 19683863
World J Hepatol. 2015 Jun 18;7(11):1581-5
pubmed: 26085917
Int J Mol Sci. 2013 Dec 02;14(12):23559-80
pubmed: 24317431
Clin Immunol. 2014 May-Jun;152(1-2):127-39
pubmed: 24667685
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Mol Cell Proteomics. 2002 Mar;1(3):197-203
pubmed: 12096119
J Thorac Oncol. 2006 Jul;1(6):513-9
pubmed: 17409910
EBioMedicine. 2015 Mar 13;2(5):438-46
pubmed: 26137588
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Tumour Biol. 2016 Feb;37(2):2547-53
pubmed: 26386724
Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):747-55
pubmed: 23462916
Cancer Sci. 2017 Mar;108(3):308-315
pubmed: 28064445
J Hepatol. 2001 Apr;34(4):570-5
pubmed: 11394657
Cancer Prev Res (Phila). 2011 Jul;4(7):1126-34
pubmed: 21733826